Targeting CD39 with a first-in-class inhibitory antibody prevents ATP processing and increases T-cell activation

被引：3

作者：

Lerner, Alana G. ^{[1
]}

Kovalenko, Maria ^{[1
]}

Welch, Megan ^{[1
]}

Dela Cruz, Tracy ^{[1
]}

Jones, Jeff ^{[1
]}

Wong, Clifford ^{[1
]}

Spatola, Bradley ^{[1
]}

Eberhardt, Meghan ^{[1
]}

Wong, Andrew ^{[1
]}

Fung, Wanchi ^{[1
]}

Lagpacan, Leanna ^{[1
]}

Losenkova, Karolina ^{[2
]}

Yegutkin, Gennady ^{[2
]}

Soros, Vanessa ^{[1
]}

Corbin, John ^{[1
]}

Beers, Courtney ^{[1
]}

Moesta, Achim K. ^{[1
]}

机构：

[1] Tizona Therapeut, San Francisco, CA USA

[2] Univ Turku, MediCity Res Lab, Turku, Finland

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-5012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5012

引用

页数：2

共 50 条

[1] Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
Chmielowski, Bartosz
JOURNAL OF SKIN CANCER, 2013, 2013
[2] T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus
Loza, Matthew J.
Anderson, A. Shane
O'Rourke, Kenneth S.
Wood, James
Khan, Islam U.
CELLULAR IMMUNOLOGY, 2011, 271 (01) : 110 - 117
[3] JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G
Obermajer, Natasa
Zwolak, Adam
van de Ven, Kelly
Versmissen, Shana
Menard, Krista
Rogers, Katharine
Petley, Ted
Weinstock, Dan
Aligo, Jason
Patel, Jaymala
Tian, Ken
Angelillo, Lorraine
Yi, Fang
Jarantow, Stephen
Schutsky, Keith
Hamuro, Yoshitomo
Arias, Diana Alvarez
Buyens, Kristel
Yao, Tsun-Wen Sheena
Torti, Vince
Brajic, Aleksandra
Geist, Brian
van Heerden, Marjolein
Chu, Gerald
Verbist, Bie
Ongenaert, Mate
Hasler, Julien
Packman, Kathryn
Shenton, Jacintha
Lenox, Laurie
Clawson, Jacalyn
Brown, Regina J.
Lauring, Josh
Greger, James G.
Brehmer, Dirk
Singh, Sanjaya
Lorenzi, Matthew, V
Laquerre, Sylvie
ISCIENCE, 2025, 28 (03)
[4] Expression of CD39 and CD73 on peripheral T-cell subsets in calcific aortic stenosis
Golovkin, A.
Kudryavtsev, I.
Serebryakova, M.
Malashicheva, A.
Shishkova, A.
Zhiduleva, E.
Moiseeva, O.
CARDIOVASCULAR RESEARCH, 2016, 111 : S97 - S97
[5] EXTRACELLULAR ATP AND CD39 REGULATE NATURAL KILLER CELL ACTIVATION AND CYTOTOXICITY DURING LIVER REGENERATION
Graubardt, Nadine
Fahrner, Rene
Trochsler, Markus
Keogh, Adrian
Robson, Simon C.
Candinas, Daniel
Beldi, Guido
HEPATOLOGY, 2010, 52 (04) : 475A - 475A
[6] Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Kashyap, Abhishek S.
Thelemann, Tamara
Klar, Richard
Kallert, Sandra M.
Festag, Julia
Buchi, Melanie
Hinterwimmer, Lisa
Schell, Monika
Michel, Sven
Jaschinski, Frank
Zippelius, Alfred
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[7] Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sezary Syndrome Patients
Bensussan, Armand
Janela, Baptiste
Thonnart, Nicolas
Bagot, Martine
Musette, Philippe
Ginhoux, Florent
Marie-Cardine, Anne
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (03) : 725 - 728
[8] CD39 EXPRESSION IN GLIOBLASTOMA TUMOR MICROENVIRONMENT DOES NOT AFFECT SURVIVAL OR T-CELL EXHAUSTION
Zheng, Allison
Pappu, Ananya
Gill, Sabraj
Stelter, Isabella
Aghi, Manish
NEURO-ONCOLOGY, 2022, 24 : 279 - 280
[9] CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer
Kortekaas, Kim E.
Santegoets, Saskia J.
Sturm, Gregor
Ehsan, Ilina
van Egmond, Sylvia L.
Finotello, Francesca
Trajanoski, Zlatko
Welters, Marij J. P.
van Poelgeest, Mariette I. E.
van der Burg, Sjoerd H.
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (10) : 1311 - 1321
[10] Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome
Sonigo, Gabrielle
Bozonnat, Alizee
Dumont, Maelle
Thonnart, Nicolas
Ram-Wolff, Caroline
de Masson, Adele
Bagot, Martine
Bensussan, Armand
Marie-Cardine, Anne
BLOOD, 2022, 139 (17) : 2712 - 2716

← 1 2 3 4 5 →